Direct
NAV (05-Jul-24)
Returns (Since Inception)
Fund Size
₹899 Cr
Expense Ratio
0.83%
ISIN
INF277K019A3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+50.00%
+45.87% (Cat Avg.)
3 Years
+17.33%
+13.78% (Cat Avg.)
5 Years
+27.74%
+26.26% (Cat Avg.)
Since Inception
+14.26%
— (Cat Avg.)
Equity | ₹871.4 Cr | 96.91% |
Others | ₹27.77 Cr | 3.09% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹117.41 Cr | 13.06% |
Aurobindo Pharma Ltd | Equity | ₹87.86 Cr | 9.77% |
Lupin Ltd | Equity | ₹80.75 Cr | 8.98% |
Dr Reddy's Laboratories Ltd | Equity | ₹62.35 Cr | 6.93% |
Cipla Ltd | Equity | ₹60.06 Cr | 6.68% |
Zydus Lifesciences Ltd | Equity | ₹47.14 Cr | 5.24% |
Divi's Laboratories Ltd | Equity | ₹45.21 Cr | 5.03% |
Fortis Healthcare Ltd | Equity | ₹40.63 Cr | 4.52% |
Alkem Laboratories Ltd | Equity | ₹36.2 Cr | 4.03% |
Apollo Hospitals Enterprise Ltd | Equity | ₹34.39 Cr | 3.83% |
Cash / Net Current Asset | Cash | ₹25.15 Cr | 2.80% |
Ajanta Pharma Ltd | Equity | ₹22.31 Cr | 2.48% |
Medi Assist Healthcare Services Ltd | Equity | ₹20.58 Cr | 2.29% |
HealthCare Global Enterprises Ltd | Equity | ₹20.42 Cr | 2.27% |
FDC Ltd | Equity | ₹20.38 Cr | 2.27% |
Torrent Pharmaceuticals Ltd | Equity | ₹19.12 Cr | 2.13% |
Orchid Pharma Ltd | Equity | ₹17.55 Cr | 1.95% |
Sanofi India Ltd | Equity | ₹16.53 Cr | 1.84% |
Ipca Laboratories Ltd | Equity | ₹16.41 Cr | 1.83% |
Jupiter Life Line Hospitals Ltd | Equity | ₹12.52 Cr | 1.39% |
Wockhardt Ltd | Equity | ₹10.24 Cr | 1.14% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹9.63 Cr | 1.07% |
Mankind Pharma Ltd | Equity | ₹8.87 Cr | 0.99% |
Piramal Pharma Ltd | Equity | ₹8.83 Cr | 0.98% |
Medplus Health Services Ltd | Equity | ₹8.69 Cr | 0.97% |
Indoco Remedies Ltd | Equity | ₹8.32 Cr | 0.93% |
Coromandel International Ltd | Equity | ₹7.84 Cr | 0.87% |
Procter & Gamble Health Ltd | Equity | ₹7.52 Cr | 0.84% |
Syngene International Ltd | Equity | ₹7.19 Cr | 0.80% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.44 Cr | 0.72% |
Ami Organics Ltd | Equity | ₹6.09 Cr | 0.68% |
Deepak Nitrite Ltd | Equity | ₹3.92 Cr | 0.44% |
A) Repo | Cash - Repurchase Agreement | ₹2.62 Cr | 0.29% |
Large Cap Stocks
38.64%
Mid Cap Stocks
39.67%
Small Cap Stocks
18.61%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹853.55 Cr | 94.93% |
Basic Materials | ₹17.85 Cr | 1.99% |
Standard Deviation
This fund
14.30%
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
0.78
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Since March 2021
ISIN | INF277K019A3 | Expense Ratio | 0.83% | Exit Load | No Charges | Fund Size | ₹899 Cr | Age | 28 Dec 2015 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Flat 15% tax on realised gains (STCG - short term capital gains)
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹13.07 Cr | 48.4% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹683.18 Cr | 48.4% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹683.18 Cr | 46.4% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹41.38 Cr | 46.7% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹156.65 Cr | 45.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹156.65 Cr | 42.3% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2201.96 Cr | 47.7% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2201.96 Cr | 45.6% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹552.77 Cr | 49.3% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹16.16 Cr | 45.6% |
Total AUM
₹1,55,659 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Your principal amount will be at Very High Risk